News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Unfortunately the trial did not meet it's endpoint of median overall survival.   I did not really expect it to as the immunotherapies appear to help only a small subset of patients, but when they do - it helps a lot.  This leads to a long tail of survivors, but the median does not change.  All of the immunotherapies by themselves will probably have this same problem.  I think the key is to combine them to the point where most people benefit.  I wouldn't write this off until we see the complete results and see if there is a signficant tail.


Posted on: 09/13/2019

Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740